Geistlich - Indication sheets X3 - Failure Management | Page 6
Indication Sheet X3
31430.1/1008/e
Failure Management
Literature references
Schwarz et al. Journal of Clinical Periodontology. 2006;33:491-499.
H
ealing of intrabony peri-implantitis defects following application of a nanocrystalline hydroxyapatite (Ostim) or a bovine-derived xenograft (Bio-Oss) in combination
with a collagen membrane (Bio-Gide). A case series.
1
Schwarz et al. Journal of Clinical Periodontology. 2006;33:584-595.
Influence of different treatment approaches on non-submerged and submerged healing of ligature induced peri-implantitis lesions: an experimental study in dogs.
2
Schwarz et al. Clinical Oral Implants Research. 2007;18:161-170.
Comparison of nat urally occurring and ligature-induced peri-implantitis bone defects in humans and dogs.
3
Schwarz et al. Journal of Clinical Periodontology. 2008;35:80-87.
T
wo-year clinical results following treatment of peri-implantitis lesions using a nanocrystalline hydroxyapatite or a natural bone mineral in combination with a collagen
membrane.
4
Schwarz et al. Journal of Clinical Periodontology. 2009;36:807-814.
S
urgical regenerative treatment of peri-implantitis lesions using a nanocrystalline hydroxyapatite or a natural bone mineral in combination with a collagen membrane:
a four-year clinical follow-up report.
5
Schwarz et al. Journal of Clinical Periodontology. 2010;37:449-455.
Impact of defect configuration on the clinical outcome following surgical regenerative therapy of periimplantitis.
6
Schwarz & Becker. Quintessence Publishing Co. Ltd. London, 2010.
Peri-implant Infection. Etiology, Diagnosis and Treatment.
7
Treatment concepts for Peri-Implantitis by PD Dr. Frank Schwarz,
Dr. Narja Sahm and Prof. Dr. Juergen Becker, Duesseldorf, Germany
Contact
> PD Dr. Frank Schwarz, Heinrich Heine University, Westdeutsche Kieferklinik, Moorenstrasse 5, 40225 Duesseldorf, Germany
telephone: +49 211 811 81 49, fax: +49 211 171 35 42, e-mail: [email protected]
> herapeutic strategies for intraosseous and supracrestal defect components.
T
> he treatment steps: decontamination, implantoplasty, and augmentation / guided bone regeneration
T
(GBR) can deliver good results.
> eistlich Bio-Oss®, Geistlich Bio-Gide® and Geistlich Mucograft® are important components of
G
treatment concepts for tissue regeneration.
Further Indication Sheets
> free delivery please contact: www.geistlich.com/indicationsheets
For
> you no longer wish to collect Indication Sheets, please unsubscribe with your local distribution partner
If
1. Synopsis: Regenerative Therapy
Criteria
Regenerative Measure
Intrabony Component
Geistlich Bio-Oss®
(0.25–1 mm)
Gesitlich Bio-Gide®
Double Layer Technique
Supracrestal Component
(< 1 mm)
Geistlich Bio-Oss®
(1–2 mm)
Contour Augmentation
Supracrestal Component
(> 1 mm)
Dehisced Areas
Implantoplasty
Thin Mucosa
Geistlich Mucograft®
Visualisation
Geistlich Pharma AG
Business Unit Biomaterials
CH-6110 Wolhusen
phone +41 41 492 56 30
fax +41 41 492 56 39
www.geistlich-pharma.com
©
5
1
6